Annual Sabin Colloquium on Cancer Vaccines and Immunotherapy

Information

  • Research Project
  • 7000735
  • ApplicationId
    7000735
  • Core Project Number
    R13CA117408
  • Full Project Number
    1R13CA117408-01
  • Serial Number
    117408
  • FOA Number
    PAR-03-176
  • Sub Project Id
  • Project Start Date
    6/10/2005 - 19 years ago
  • Project End Date
    5/31/2006 - 18 years ago
  • Program Officer Name
    DUGLAS-TABOR, YVONNE
  • Budget Start Date
    6/10/2005 - 19 years ago
  • Budget End Date
    5/31/2006 - 18 years ago
  • Fiscal Year
    2005
  • Support Year
    1
  • Suffix
  • Award Notice Date
    6/10/2005 - 19 years ago

Annual Sabin Colloquium on Cancer Vaccines and Immunotherapy

DESCRIPTION (provided by applicant): The Albert B. Sabin Vaccine Institute requests a $250,000 grant to support the Annual Sabin Colloquium on Cancer Vaccines & Immunotherapy for a 5-year project period. The Annual Sabin Colloquium on Cancer Vaccines & Immunotherapy was established in 1999, by the Albert B. Sabin Vaccine Institute, to bring together leading cancer vaccine researchers from academia, industry and government to participate in three days of open discussion of ideas and data. The Albert B. Sabin Vaccine Institute is a non-profit public organization dedicated to continuing the work of Dr. Albert B. Sabin, who envisioned the tremendous potential of vaccines to prevent deadly diseases. The Institute promotes rapid scientific advances in vaccine development, delivery, and distribution worldwide. The Institute is dedicated to finding innovative and effective solutions, and attempts to build bridges of communication and discovery between research, clinical medicine, academia, business, and government. The Sabin Vaccine Institute (SVI) convenes this annual colloquium with the goal of shortening the time needed to translate scientific discoveries into meaningful treatments for cancer. Participants share unpublished data and conclusions that may generate new ideas and forge partnerships and collaborations. By speeding the exchange of information, by taking a fresh look at cancer research paradigms, and by fostering new collaborations among top-level scientists, the Colloquium on Cancer Vaccines and Immunotherapy catalyzes research and development of vaccines to treat and prevent cancer. Approximately 40 scientists participate in the Colloquium annually. The upcoming Colloquium, the 1st in the proposed 5-year project period, will be held June 21-24, 2005 at Cold Spring Harbor Laboratory. The Sabin Colloquium on Cancer Vaccines and Immunotherapy makes a measurable impact on the pace of development of vaccines to prevent and treat cancer. Participants have formed new, dynamic collaborations with partners they met at the colloquium. From the Colloquium gatherings, participants return to their laboratories to test new concepts that affect the direction of cancer research through their individual and collective influence. The SVI leverages the Colloquium's impact by publishing the proceedings in book form and on the Internet, and by publishing a summary report in a peer review biomedical journal.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R13
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    9000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    396
  • Ed Inst. Type
  • Funding ICs
    NCI:9000\
  • Funding Mechanism
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ALBERT B. SABIN VACCINE INSTITUTE
  • Organization Department
  • Organization DUNS
    849900175
  • Organization City
    WASHINGTON
  • Organization State
    DC
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    20006
  • Organization District
    UNITED STATES